NASDAQ · Biotechnology

ENTA (ENTA) Stock

$12.61 -0.94% NASDAQ: ENTA Healthcare

Valuation

MetricValue
Price$12.61
Market Cap$366.68M
P/E Ratio-6.04
P/B Ratio2.94
P/S Ratio3.95
EPS (TTM)$-3.84
52-Week High$17.15
52-Week Low$6.43
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.00%
ROA-11.84%
ROCE-130.77%
Gross Margin98.25%
Operating Margin-87.24%
Net Margin-89.56%
Debt/Equity1.60
Current Ratio4.16

Annual Financials (USD)

Metric20212022202320242025
Revenue$97.0M$86.0M$79.0M$68.0M$65.0M
Operating Profit$-110.0M$-124.0M$-137.0M$-122.0M$-85.0M
Net Profit$-79.0M$-122.0M$-134.0M$-116.0M$-82.0M
EPS$-3.92$-5.91$-6.38$-5.48$-3.84
Op Margin-112.9%-143.7%-173.2%-179.9%-130.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$441.0M$381.0M$462.0M$377.0M$281.0M
Total Liabilities$41.0M$59.0M$246.0M$248.0M$216.0M
Cash$57.0M$44.0M$85.0M$37.0M$32.0M
Borrowings$7.0M$27.0M$27.0M$226.0M$201.0M

Latest News

Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria MT Newswires · Apr 13, 2026 Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Business Wire · Apr 13, 2026 Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 Business Wire · Apr 7, 2026 Top Premarket Decliners MT Newswires · Apr 6, 2026 Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) Business Wire · Mar 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-70.0M$-85.0M$-103.0M$-79.0M$-19.0M
Investing Cash Flow$36.0M$53.0M$-63.0M$40.0M$27.0M
Financing Cash Flow$-1.0M$-1.0M$-4.0M$0$0
Net Cash Flow$-30.0M$-10.0M$41.0M$-48.0M$-6.0M
Free Cash Flow$-71.0M$-87.0M$-112.0M$-97.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-20.51
EV / EBITDA-6.65
FCF Yield-3.51%
Quick Ratio3.84
Interest Coverage-10.62
Return 1Y67.53%
Return 3Y-29.73%
Return 5Y-68.86%

Ownership

Insiders Held4.69%
Institutions Held91.57%
Institutions Float Held96.08%
Institutional HolderSharesReport Date
Janus Henderson Group PLC3,729,6592025-12-31
Blackrock Inc.3,076,2822025-12-31
Farallon Capital Management LLC2,772,2622025-12-31
Krensavage Asset Management, LLC2,766,3902025-12-31
Vanguard Group Inc2,301,7942025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%
IMRX $4.24 -2.75% -3.94 $153.92M 0.00%

About ENTA

ENTA is led by CEO Jay R. Luly, employs 131 people, headquartered in US, publicly traded since 2013.

ENTA stock trades at $12.61 with a market capitalization of $366.68M. The stock is valued at a price-to-earnings (P/E) ratio of -6.04, price-to-book of 2.94, price-to-sales of 3.95. Over the past 52 weeks the stock has ranged between $6.43 and $17.15, and currently trades 26.5% below its 52-week high.

On profitability, ENTA generates a return on equity (ROE) of -59.00%, return on capital employed of -130.77%, an operating margin of -87.24%, a net profit margin of -89.56%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides